title: [Should we always use EGFR mutation analysis prior to palliative firstline therapy of metastatic adenocarcinoma of the lung? Contra].
authors.affiliation: Pneumologische Onkologie, Asklepios Klinik Gauting GmbH. j.pawel@asklepios.com
authors.forename: J
authors.initials: J
authors.lastname: von Pawel
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics* / Q000556:secondary / Q000628:therapy*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics*; D018773:Genes, erbB-1 / Q000187:drug effects / Q000235:genetics; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics* / Q000473:pathology / Q000628:therapy*; D009154:Mutation; D010166:Palliative Care; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors
chemical_list: D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases